NEW YORK, Nov. 7, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global DPP IV Inhibitors Industry
This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million by the following drugs – Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors (including Linagliptin and Alogliptin among others). The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 31 companies including many key and niche players such as Arisaph Pharmaceuticals, Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly And Company, Merck & Co, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, and Takeda Pharmaceutical Company Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
2. INDUSTRY OVERVIEW 4
Market Outlook 4
Major Events in the DPP-IV Inhibitor Space 5
Current and Future Analysis 5
The Diabetic Epidemic 6
Type-2 Diabetes Treatment - A Brief Overview 6
Overview of Drug Classes in Anti-Diabetic Drugs Category 7
Rationale for Use of DPP-4 Inhibitors 7
Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction 8
DPP-4 Inhibitors - Complementing Existing Approaches 8
Outlook for DPP-IV Therapies Remains Robust 8
DPP-4 Inhibitors versus GLP-1 Receptor Agonists 9
Distinction Between GLP-1 Receptor Agonists and DPP-4 Inhibitors 9
Hunt for Novel Therapeutic Areas Attracts Pharma to DPP-4 Market 9
Limited Efficacy Drives Use of Combination Products 10
3. DPP-IV INHIBITORS - MARKET DYNAMICS 11
The DPP-4 Inhibitor Domain 11
Select Approved DPP-4 Inhibitors in Developed Markets 11
Januvia - The Leading DPP-IV Inhibitor Drug Worldwide 12
Huge Potential Exists for Januvia and Other DPP-4 Inhibitors 12
Januvia to Concede Market Share; Yet Remain the Market Leader 12
"Me-Too" Competition Fails to Halt Januvia's Success 13
Galvus Sales Garner Significant Growth 13
A Comparison of Januvia and Galvus 13
Pharmacological Comparison of Sitagliptin and Vildagliptin 14
Anti-Diabetics Arena in a Quandary as Late Stage Development
Drug Faces Trouble 14
Increasing Competition to Taper Opportunities for Pipeline Drugs 15
4. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS 16
Januvia® Franchise (Merck & Co.) 16
Table 1: Global Sales of Januvia (Sitagliptin) Franchise by
Drug (2007-2010): Value Sales in US$ Million for Januvia and
Janumet (includes corresponding Graph/Chart) 17
Table 2: Global Sales of Januvia by Region (2007-2010): Value
Sales in US$ Million for US and Rest of World (includes
corresponding Graph/Chart) 17
Table 3: Global Sales of Janumet by Region (2007-2010): Value
Sales in US$ Million for US and Rest of World (includes
corresponding Graph/Chart) 18
Galvus (Novartis) 18
Onglyza (Bristol-Myers Squibb and AstraZeneca) 19
Table 4: Global Sales of Onglyza (Saxagliptin) Franchise by
Region (2009 & 2010): Value Sales in US$ Million for the US
and Rest of World (includes corresponding Graph/Chart) 19
Tradjenta (Boehringer Ingelheim) 20
A Brief Comparison of Select Marketed Drugs 20
DPP-IV Inhibitor Pipeline 21
5. DIABETES INCIDENCE AND PREVALENCE 22
Table 5: Worldwide Prevalence of Diabetes Mellitus by Region:
2010 & 2030 (includes corresponding Graph/Chart) 22
Diabetes Mellitus Cases Worldwide - A Demographic Analysis by
Geographic Region 23
North America 23
The United States 23
Canada 23
Mexico 23
Table 6: Prevalence of Diabetes Mellitus in North America
(2010 & 2030): Breakdown by Country, Age Group, and Gender
(In '000 People & %) 23
Europe 23
Table 7: Prevalence of Diabetes Mellitus in Europe (2010 &
2030): Breakdown by Country, Age Group, and Gender (In '000
People & %) 24
Asia-Pacific 25
Table 8: Prevalence of Diabetes Mellitus in South East Asia
(2010 & 2030): Breakdown by Country, Age Group, and Gender
(In '000 People & %) 25
Table 9: Prevalence of Diabetes Mellitus in Western Asia
(2010 & 2030): Breakdown by Country, Age Group, and Gender
(In '000 People & %) 26
South & Central America 26
Table 10: Prevalence of Diabetes Mellitus in South & Central
America (2010 & 2030): Breakdown by Country, Age Group, and
Gender (In '000 People & %) 27
Rest of World 28
Table 11: Prevalence of Diabetes Mellitus in Africa (2010 &
2030): Breakdown by Country, Age Group, and Gender (In '000
People & %) 28
Table 12: Prevalence of Diabetes Mellitus in The Middle East
& North Africa (2010 & 2030): Breakdown by Country, Age
Group, and Gender (In '000 People & %) 29
6. DPP-IV INHIBITORS - AN OVERVIEW OF THE DRUG CLASS 30
Physiology of Glucose Homeostasis 30
Glucose Homeostasis in the Fasting Stage 30
Glucose Homeostasis in the Fed Stage 30
What is DPP-4? 30
Introduction to DPP-4 Inhibitors 30
Mechanism of Action of DPP-4 Inhibitors 31
Schematic Representation of DPP-IV Inhibitor' Mechanism of
Action 31
DPP-4 Inhibitors in Combination with Other Anti-diabetic
Medications 31
Advantages of DPP-4 Inhibitors 32
Type-2 Diabetes - The Most Prevalent Form of Diabetes 32
Bio-chemistry of T2DM 32
7. PRODUCT APPROVALS/INTRODUCTIONS 34
Boehringer, Eli Lilly Obtain European Marketing Authorization
for Trajenta 34
Boehringer, Eli Lilly's Tradjenta Receives FDA Approval 34
Bristol-Myers and AstraZeneca Launch Kombiglyze™ XR in the US 34
Bristol-Myers and AstraZeneca Obtain EU Approval for New
Saxagliptin Label Update 35
Ono Pharmaceutical Obtains Additional Indication for Glactiv
in Japan 35
Takeda Obtains Label Extension for Nesina in Japan 35
AstraZeneca and BMS Obtain FDA Approval for Kombiglyze™ XR 36
Novartis Obtains Approval for Vildagliptin in Japan 36
Ono and Banyu Launch Glactiv in Japan 36
Takeda Launches Nesina® in Japan 36
Merck, Sharp & Dohme Introduces Januvia in China 37
Ono and Banyu Receive Japanese Approval for Sitagliptin 37
AstraZeneca and Bristol-Myers Receive EU Marketing
Authorization for Onglyza 37
AstraZeneca and Bristol-Myers Obtain FDA Clearance for Onglyza 37
Merck's Janumet™ Receives EU Approval 38
MSD Pharmaceuticals Introduces Januvia in India 38
Merck Launches Januvia in New Zealand 38
Novartis Obtains EU Approval for Combination Diabetes Drug -
Eucreas 39
Novartis' Diabetes Drug - Galvus Receives EU Approval 39
MSD's JANUVIA® Obtains EU Approval for Treatment of Type 2
Diabetes 39
Merck Obtains FDA Approval for Januvia 40
8. RECENT INDUSTRY ACTIVITY 41
Takeda Resubmits 2 NDAs for Alogliptin in the US 41
Astellas to Divest DPP-4 Inhibitor Patents to Royal Pharma 41
Sun Pharmaceutical Enters into a Partnership Deal with Merck 41
Boehringer Ingelheim and Lilly Enter into Licensing Agreement 41
Kowa Initiates Phase-II Trial of Anagliptin 42
Phenomix Shuts Shop in the Wake of Breakdown of Dutogliptin Deal 42
Forest Labs Opts Out of Anti-Diabetic Drug Deal with Phenomix 42
Double-Crane and LG Life Sciences Enter Agreement for Sale of
LC-15-0444 42
Bristol-Myers Squibb Enters into Collaboration with AstraZeneca 43
Takeda Terminates Development of TAK 100 43
Merck Obtains Positive Opinion from CHMP for Use of
sitagliptin with Insulin 43
Merck and Cigna Ink "Performance-Based Contract" 43
Novartis Terminates Eucreas Development Program in the US 43
Chiesi and Phenomix Ink Development and Commercialization Deal
for Dutogliptin 44
America Stem Cell and Dara Biosciences Sign Material Transfer
Agreement 44
Egis Acquires Marketing License for Januvia in Hungary 44
Novartis Joins Hands with USV to Market Galvus in India 44
Merck and Almirall Enter into an Agreement to Commercialize
Tesavell in Spain 45
Forest Teams Up with Phenomix for Developing DPP-IV Inhibitor
- Dutogliptin 45
Sanwa Kagaku and Kowa Ink Deal to Co-develop DPP-4 inhibitor -
SK-0403 45
Novartis' Diabetes Drug Galvus Faces Delay in FDA Approval 45
9. FOCUS ON SELECT GLOBAL PLAYERS 46
Arisaph Pharmaceuticals, Inc. (US) 46
AstraZeneca Plc. (UK) 46
Boehringer Ingelheim GmbH (Germany) 47
Bristol-Myers Squibb (US) 47
Eli Lilly And Company (US) 48
Merck & Co, Inc. (US) 48
Mitsubishi Tanabe Pharma Corporation (Japan) 49
Novartis AG (Switzerland) 50
Takeda Pharmaceutical Company Limited (Japan) 50
10. GLOBAL MARKET PERSPECTIVE 51
Table 13: World Recent Past, Current and Future Analysis for
DPP-IV Inhibitors by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 51
Table 14: World 10-Year Perspective for DPP-IV Inhibitors by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 52
Table 15: World Recent Past, Current and Future Analysis for
DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin,
Saxagliptin and Others Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) 53
Table 16: World 10-Year Perspective for DPP-IV Inhibitors by
Drug Class - Percentage Breakdown of Dollar Sales for
Sitagliptin, Vildagliptin, Saxagliptin and Others Markets for
Years 2008, 2011 and 2017 (includes corresponding Graph/Chart) 54
11. THE UNITED STATES 55
A.Market Analysis 55
Current & Future Analysis 55
Diabetes Pandemic in the US 55
Non-Insulin Products Dominate the Diabetes Therapeutics Market 55
Table 17: US Non-Insulin Anti-Diabetic Market by Drug Class
(2010 & 2017): Percentage Breakdown of Revenues for
Metformin, DPP-4 Inhibitors, Sulfonylureas,
Thiazolidinediones, GLP-1 Analogues, and Others (includes
corresponding Graph/Chart) 56
DPP-IV Inhibitors All Set to Gain Market Share in Oral Anti
-Diabetics 56
Januvia Leads the Way, Will Remain the Top Drug Through 2017 56
Minimal Differentiation Affects Sales of Onglyza 57
Table 18: US Total Prescriptions of Januvia and Onglyza
Analyzed in Terms of Total Prescriptions Since Launch in
Thousands (includes corresponding Graph/Chart) 57
FDA's Issue of Safety Alert on Januvia and Janumet 58
Increasing Scrutiny of NDAs Bodes Tough Time for New Drugs 58
Product Approvals/Launches 59
Strategic Corporate Developments 61
Focus on Select Key Players 63
B.Market Analytics 66
Table 19: The US Recent Past, Current and Future Analysis
for DPP-IV Inhibitors Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 66
12. CANADA 67
Market Analysis 67
Table 20: Canadian Recent Past, Current and Future Analysis
for DPP-IV Inhibitors Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 67
13. JAPAN 68
A.Market Analysis 68
Current & Future Analysis 68
Competition in Japanese DPP-IV Inhibitor Market Heats Up 68
Product Approvals/Launches 68
Strategic Corporate Developments 70
Focus on Select Key Players 71
B.Market Analytics 72
Table 21: Japanese Recent Past, Current and Future Analysis
for DPP-IV Inhibitors Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 72
14. EUROPE 73
A.Market Analysis 73
Current & Future Analysis 73
Treatment Strategies of Type-2 Diabetes in Europe 73
Product Approvals/Launches 73
Strategic Corporate Developments 76
B.Market Analytics 78
Table 22: European Recent Past, Current and Future Analysis
for DPP-IV Inhibitors by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) 78
Table 23: European 10-Year Perspective for DPP-IV Inhibitors
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2008, 2011 and 2017 (includes corresponding
Graph/Chart) 79
14a. FRANCE 80
Market Analysis 80
Table 24: French Recent Past, Current and Future Analysis
for DPP-IV Inhibitors Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 80
14b. GERMANY 81
A.Market Analysis 81
Boehringer Ingelheim GmbH - A Key Player 81
B.Market Analytics 82
Table 25: German Recent Past, Current and Future Analysis
for DPP-IV Inhibitors Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 82
14c. ITALY 83
Market Analysis 83
Table 26: Italian Recent Past, Current and Future Analysis
for DPP-IV Inhibitors Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 83
14d. THE UNITED KINGDOM 84
A.Market Analysis 84
Current & Future Analysis 84
Blacklisting of Drugs in UK Raises Concerns 84
AstraZeneca Plc. - A Key Player 84
B.Market Analytics 85
Table 27: The UK Recent Past, Current and Future Analysis
for DPP-IV Inhibitors Analyzed with Annual Sales Figures in
US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 85
14e. REST OF EUROPE 86
A.Market Analysis 86
Novartis AG - A Major Player 86
B.Market Analytics 87
Table 28: Rest of European Recent Past, Current and Future
Analysis for DPP-IV Inhibitors Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 87
15. ASIA-PACIFIC 88
A.Market Analysis 88
Current & Future Analysis 88
Overview of Select Markets in the Region 88
India 88
DPP-4 Inhibitor to Garner Increasing Share in Indian
Diabetes Drugs Market 88
Strong Growth Ahead for Anti-Diabetes Products in India 88
First-to-Market Advantage and Unique Strategy Keep Januvia
Ahead of Competition 89
China 89
China Lags in DPP-4 Inhibitors Market, Bodes Robust Growth
Ahead 89
Australia 90
Rising Incidence of Diabetes 90
Diabetes Market - A Window of Opportunity Restricted by PBS 90
Korea 91
Januvia Franchise Reigns in Korean DPP- IV Market 91
Product Approvals/Launches 91
Strategic Corporate Developments 92
B.Market Analytics 93
Table 29: Asia-Pacific Recent Past, Current and Future
Analysis for DPP-IV Inhibitors Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 93
16. REST OF WORLD 94
A.Market Analysis 94
Current & Future Analysis 94
A Sneak-Peak at Brazilian Diabetes Market 94
B.Market Analytics 95
Table 30: Rest of World Recent Past, Current and Future
Analysis for DPP-IV Inhibitors Analyzed with Annual Sales
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) 95
COMPETITIVE LANDSCAPE
Total Companies Profiled: 31 (including Divisions/Subsidiaries - 33)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 10
Japan 10
Europe 7
Germany 1
The United Kingdom 1
Italy 1
Spain 1
Rest of Europe 3
Asia-Pacific (Excluding Japan) 6
------------------------------------------
To order this report:
Biopharmaceutical Industry: Global DPP IV Inhibitors Industry
Biopharmaceutical Business News
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article